药物涂层球囊对比普通球囊治疗动静脉瘘狭窄的荟萃分析
该系统评价与荟萃分析纳入12项研究共979例患者,比较药物涂层球囊血管成形术(DCBA)与普通球囊血管成形术(BA)治疗动静脉瘘(AVF)狭窄的效果。结果显示DCBA组6个月和12个月靶病变血运重建(TLR)显著少于BA组,技术成功率和12个月死亡率无显著差异。亚组分析显示DCBA的优越性仅见于队列研究而非随机对照试验。
要点
- DCBA治疗AVF狭窄的6个月TLR显著低于BA(OR 0.31,95%CI 0.14-0.69,p=0.004)。
- DCBA的12个月TLR也显著低于BA(OR 0.45,95%CI 0.21-0.97,p=0.04)。
- 技术成功率和12个月死亡率两组无显著差异,但需更大规模随机研究证实。
核心结论
- 在原发或复发性AVF狭窄中,DCBA相比BA与更低的6个月和12个月TLR相关。
- DCBA与BA的技术成功率和12个月死亡率无显著差异。
- 需要更大规模的随机对照研究才能得出确定性结论。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed和Embase数据库1966年至2019年5月的英文文献。
- 纳入12项研究(6项随机对照试验和6项队列研究),共979例患者。
- 采用随机效应模型合并OR和95%CI,并进行亚组和敏感性分析。
主要发现
- DCBA组6个月TLR的合并OR为0.31(95%CI 0.14-0.69,p=0.004),显著低于BA组。
- DCBA组12个月TLR的合并OR为0.45(95%CI 0.21-0.97,p=0.04),显著低于BA组。
- 技术成功率的合并OR为0.22(95%CI 0.03-1.43,p=0.11),两组无显著差异。
- 12个月死亡率的合并OR为0.71(95%CI 0.20-2.51,p=0.60),两组无显著差异。
- 亚组分析显示DCBA在队列研究中优于BA,但在随机对照试验中未显示优势且异质性高;队列研究存在显著发表偏倚。
关键数值与推荐
- 6个月TLR:DCBA vs BA的OR 0.31(95%CI 0.14-0.69,p=0.004)。
- 12个月TLR:DCBA vs BA的OR 0.45(95%CI 0.21-0.97,p=0.04)。
- 技术成功率:OR 0.22(95%CI 0.03-1.43,p=0.11)。
- 12个月死亡率:OR 0.71(95%CI 0.20-2.51,p=0.60)。
临床怎么用
- 对于原发或复发性AVF狭窄,DCBA可考虑作为降低6个月和12个月TLR的选项。
- 技术成功率和死亡率与BA相当,但需结合随机对照试验证据谨慎应用。
局限性
- 纳入研究包括6项队列研究,可能存在发表偏倚(队列研究中显著)。
- 随机对照试验亚组未显示DCBA优于BA且异质性高。
- 样本量有限(979例),需要更大规模随机对照研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To compare the effectiveness and safety outcomes of drug-coated balloon angioplasty (DCBA) vs conventional balloon angioplasty (BA) for arteriovenous fistula (AVF) stenosis. Materials and Methods: A systematic review was conducted of PubMed and Embase databases from 1966 to May 2019 to identify English-language articles evaluating DCBA vs BA for the treatment of AVF stenosis. Data extracted from each study were synthesized to evaluate target lesion revascularization (TLR), technical success, and mortality for the 2 approaches. Meta-analyses were performed on these outcomes using random effects models to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). Subgroup and sensitivity analyses were performed. Results: Twelve studies [6 randomized controlled trials (RCTs) and 6 cohort studies] comprising 979 patients were included in this meta-analysis. The pooled results showed that AVFs treated with DCBA had significantly fewer TLRs at 6 months (OR 0.31, 95% CI 0.14 to 0.69, p=0.004) and 12 months (OR 0.45, 95% CI 0.21 to 0.97, p=0.04) than BA. The 2 approaches had similar technical success rates (OR 0.22, 95% CI 0.03 to 1.43, p=0.11). Additionally, the pooled OR of 12-month mortality was 0.71 (95% CI 0.20 to 2.51, p=0.60), indicating no significant difference between DCBA and BA. Subgroup analysis based on study design showed the superiority of DCBA to BA in cohort studies but not RCTs, which had high heterogeneity. Significant publication bias was found in the cohort studies. Conclusion: In de novo or recurrent AVF stenosis, DCBA appears to be an effective procedure associated with lower 6- and 12-month TLR compared with BA. However, larger and randomized controlled studies are warranted to draw definitive conclusions.
引用
- Cao Z, Li J, Zhang T, et al. Comparative Effectiveness of Drug-Coated Balloon vs Balloon Angioplasty for the Treatment of Arteriovenous Fistula Stenosis: A Meta-analysis. J Endovasc Ther. 2020. PMID: 32043432. doi:10.1177/1526602820902757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。